Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis
Recruitment Status: recruiting as of August 2020.
Estimated Completion Date: July 2021
Sponsors and Collaborators: CSL Behring
Information provided by (Responsible Party): CSL Behring
Brief Summary: Study CSL324_1002 will investigate the safety and pharmacokinetics of repeat doses of CSL324 in subjects with hidradenitis suppurativa and palmoplantar pustulosis. CSL324 is a novel, recombinant therapy that may treat diseases caused by increased numbers of neutrophils at sites of inflammation.
Please link complete details https://clinicaltrials.gov/ct2/show/NCT03972280
Contact: Trial Register Coordinator, 610-878-4000, email@example.com